Thus, the previously reported nongenotropic effects of androgen receptor on bone growth and prostate cancer cell survival [32, 33, 34] are unlikely to have a role in resistance to antiandrogen ...

Objective: To present management options for gynaecomastia and mastodynia associated with nonsteroidal antiandrogen therapy, supported by relevant data and case studies. Background: Gynaecomastia ...

BACKGROUND: Transgender women are individuals born male but identify as female. Many transgender women undergo gender-affirming hormone therapy to alleviate the distress that can occur due to gender ...

On June 11, 2024, Catalent Pharma Solutions, LLC, submitted a notification of proposed production activity to the FTZ Board for its facility within FTZ 29, in Winchester, Kentucky. The notification ...

The nonsteroidal antiandrogen darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) led to improvements in radiological progression-free survival (rPFS) in patients with metastatic ...

Even if T cell exhaustion may be reduced with antiandrogen treatment, the initial neoantigen presentation and infiltration into the tumours can also be compromised, cancelling out the beneficial ...

UBE2J1, E2 Ubiquitin-Conjugating Enzyme, Androgen Receptor Degradation, Regulating Androgen Receptor Degradation, Antiandrogen Resistance, androgen receptor (AR) signaling, androgen receptor gene ...

Abstract. Targeting androgen receptor (AR) by pharmacologic intervention is one of the practical approaches for the treatment of castration-resistant prostate cancer (CRPC). Hence, this study aimed to ...

Incorporation of curcumin and β-ionone into one chemical entity led to identification of a novel antiandrogen with two bulky side chains, 6, which is a pure antagonist of the wild-type and the T877A, ...